172 related articles for article (PubMed ID: 18451239)
1. A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.
Liu G; Kolesar J; McNeel DG; Leith C; Schell K; Eickhoff J; Lee F; Traynor A; Marnocha R; Alberti D; Zwiebel J; Wilding G
Clin Cancer Res; 2008 May; 14(9):2732-9. PubMed ID: 18451239
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
Moulder SL; Symmans WF; Booser DJ; Madden TL; Lipsanen C; Yuan L; Brewster AM; Cristofanilli M; Hunt KK; Buchholz TA; Zwiebel J; Valero V; Hortobagyi GN; Esteva FJ
Clin Cancer Res; 2008 Dec; 14(23):7909-16. PubMed ID: 19047121
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
[TBL] [Abstract][Full Text] [Related]
6. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.
Rudin CM; Otterson GA; Mauer AM; Villalona-Calero MA; Tomek R; Prange B; George CM; Szeto L; Vokes EE
Ann Oncol; 2002 Apr; 13(4):539-45. PubMed ID: 12056703
[TBL] [Abstract][Full Text] [Related]
7. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
[TBL] [Abstract][Full Text] [Related]
8. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.
Fidias P; Pennell NA; Boral AL; Shapiro GI; Skarin AT; Eder JP; Kwoh TJ; Geary RS; Johnson BE; Lynch TJ; Supko JG
J Thorac Oncol; 2009 Sep; 4(9):1156-62. PubMed ID: 19704336
[TBL] [Abstract][Full Text] [Related]
10. Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.
Morris MJ; Cordon-Cardo C; Kelly WK; Slovin SF; Siedlecki K; Regan KP; DiPaola RS; Rafi M; Rosen N; Scher HI
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):6-13. PubMed ID: 15722787
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
Lopes de Menezes DE; Mayer LD
Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
[TBL] [Abstract][Full Text] [Related]
12. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
Marcucci G; Byrd JC; Dai G; Klisovic MI; Kourlas PJ; Young DC; Cataland SR; Fisher DB; Lucas D; Chan KK; Porcu P; Lin ZP; Farag SF; Frankel SR; Zwiebel JA; Kraut EH; Balcerzak SP; Bloomfield CD; Grever MR; Caligiuri MA
Blood; 2003 Jan; 101(2):425-32. PubMed ID: 12393493
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
Galatin PS; Advani RH; Fisher GA; Francisco B; Julian T; Losa R; Sierra MI; Sikic BI
Invest New Drugs; 2011 Oct; 29(5):971-7. PubMed ID: 20349264
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors.
Stein MN; Goodin S; Gounder M; Gibbon D; Moss R; Portal D; Lindquist D; Zhao Y; Takebe N; Tan A; Aisner J; Lin H; Ready N; Mehnert JM
Invest New Drugs; 2020 Jun; 38(3):855-865. PubMed ID: 31388792
[TBL] [Abstract][Full Text] [Related]
18. A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers.
Ma WW; Zhu M; Lam ET; Diamond JR; Dy GK; Fisher GA; Goff LW; Alberts S; Bui LA; Sanghal A; Kothekar M; Khopade A; Chimote G; Faulkner R; Eckhardt SG; Adjei AA; Jimeno A
Cancer Chemother Pharmacol; 2021 Jun; 87(6):779-788. PubMed ID: 33634324
[TBL] [Abstract][Full Text] [Related]
19. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C
J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
Dy GK; Bruzek LM; Croghan GA; Mandrekar S; Erlichman C; Peethambaram P; Pitot HC; Hanson LJ; Reid JM; Furth A; Cheng S; Martell RE; Kaufmann SH; Adjei AA
Clin Cancer Res; 2005 Mar; 11(5):1877-83. PubMed ID: 15756013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
